Results from a phase Ia/Ib Study of ESG401, a novel Trop2 antibody-drug conjugate, in patients with different subtypes of metastatic breast cancer

被引：0
|
作者：
Ma, F. [1 ]
Qiu, F. [2 ]
Tong, Z. [3 ]
Wang, J. [4 ]
Shi, Y. [5 ]
Zhang, Y. [2 ,10 ]
Yu, G. [6 ]
Shi, H. [7 ]
Wu, X. [8 ]
Liu, A. [9 ]
Zhang, Y. [2 ,10 ]
Wang, H. [11 ]
Cheng, Y. [12 ]
Yang, H. [13 ]
Li, H. [14 ]
Chang, J. [15 ]
Xing, X. [16 ]
机构：
[1] Chinese Acad Med Sci & Peking Union Med Coll, Natl Canc Ctr, Canc Hosp, Med Oncol Dept, Beijing, Peoples R China
[2] Zhejiang Univ, Affiliated Hosp 2, Sch Med, Med Oncol, Hangzhou, Zhejiang, Peoples R China
[3] TMUCIH Tianjin Med Univ Canc Inst & Hosp, Dept Breast Canc Pathol, Tianjin, Peoples R China
[4] Chinese Acad Med Sci & Peking Union Med Coll, Canc Hosp, Med Oncol, Beijing, Peoples R China
[5] TMUCIH Tianjin Med Univ Canc Inst & Hosp, Med Oncol Dept Breast Canc, Tianjin, Peoples R China
[6] Weifang Peoples Hosp, Med Oncol, Weifang, Peoples R China
[7] Gannan Med Univ, Affiliated Hosp 1, Med Oncol, Ganzhou, Peoples R China
[8] Hubei Canc Hosp, Mammary Ctr, Wuhan, Peoples R China
[9] Nanchang Univ, Affiliated Hosp 2, Med Oncol, Nanchang, Jiangxi, Peoples R China
[10] Beijing Hosp, Med Oncol, Beijing, Peoples R China
[11] Nanchang Med Coll, Nanchang Peoples Hosp, Breast Oncol Dept, Nanchang, Jiangxi, Peoples R China
[12] Jilin Canc Hosp, Med Oncol, Changchun, Jilin, Peoples R China
[13] Hebei Univ, Affiliated Hosp, Med Oncol, Baoding, Peoples R China
[14] Peking Univ Canc Hosp & Inst, Breast Med, Beijing, Peoples R China
[15] Guizhou Med Univ, Affiliated Hosp, Breast Oncol Dept, Guiyang, Guizhou, Peoples R China
[16] Shanghai Escugen Biotechnol Co Ltd, Clin Dev Dept, Shanghai, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2024年 / 35卷
关键词：
D O I：
10.1016/j.annonc.2024.08.297
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
349MO
引用
收藏
页码：S361 / S362
页数：2
相关论文
共 50 条
  • [41] A phase I study of A166, a novel anti-HER2 antibody-drug conjugate (ADC), in patients with locally advanced/metastatic solid tumors
    Lopez, Diana M.
    Barve, Minal
    Wang, Judy
    Bullock, Andrea J.
    Pectasides, Eirini
    Vaishampayan, Ulka
    Spira, Alexander I.
    Ulahannan, Susanna
    Patnaik, Amita
    Sanborn, Rachel E.
    Cicic, Dragan
    Ang, Qiuqing
    Bergonio, Gregory
    Ahnert, Jordi Rodon
    MOLECULAR CANCER THERAPEUTICS, 2019, 18 (12)
  • [42] Sacituzumab govitecan, a Trop-2-directed antibody-drug conjugate, for patients with epithelial cancer: final safety and efficacy results from the phase I/II IMMU-132-01 basket trial
    Bardia, A.
    Messersmith, W. A.
    Kio, E. A.
    Berlin, J. D.
    Vahdat, L.
    Masters, G. A.
    Moroose, R.
    Santin, A. D.
    Kalinsky, K.
    Picozzi, V
    O'Shaughnessy, J.
    Gray, J. E.
    Komiya, T.
    Lang, J. M.
    Chang, J. C.
    Starodub, A.
    Goldenberg, D. M.
    Sharkey, R. M.
    Maliakal, P.
    Hong, Q.
    Wegener, W. A.
    Goswami, T.
    Ocean, A. J.
    ANNALS OF ONCOLOGY, 2021, 32 (06) : 746 - 756
  • [43] Phase I Trial of a Novel Anti-HER2 Antibody-Drug Conjugate, ARX788, for the Treatment of HER2-Positive Metastatic Breast Cancer br
    Zhang, Jian
    Ji, Dongmei
    Shen, Weina
    Xiao, Qin
    Gu, Yajia
    'Shaughnessy, Joyce
    Hu, Xichun
    CLINICAL CANCER RESEARCH, 2022, 28 (19) : 4212 - 4221
  • [44] A randomized phase 2 study of the antibody-drug conjugate CDX-011 in advanced GPNMB-overexpressing breast cancer: The EMERGE study
    Yardley, D. A.
    Weaver, R.
    Melisko, M. E.
    Saleh, M. N.
    Arena, F. P.
    Forero, A.
    Cigler, T.
    Stopeck, A.
    Citron, D.
    Oliff, I.
    Bechhold, R.
    Loutfi, R.
    Garcia, A.
    Crowley, E.
    Green, J.
    Yellin, M. J.
    Davis, T. A.
    Vandat, L. T.
    CANCER RESEARCH, 2012, 72
  • [45] Phase I Study of Trastuzumab-DM1, an HER2 Antibody-Drug Conjugate, Given Every 3 Weeks to Patients With HER2-Positive Metastatic Breast Cancer
    Krop, Ian E.
    Beeram, Muralidhar
    Modi, Shanu
    Jones, Suzanne F.
    Holden, Scott N.
    Yu, Wei
    Girish, Sandhya
    Tibbitts, Jay
    Yi, Joo-Hee
    Sliwkowski, Mark X.
    Jacobson, Fred
    Lutzker, Stuart G.
    Burris, Howard A.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (16) : 2698 - 2704
  • [46] Phase Ia, first-in-human study of AbGn-107, a novel antibody-drug conjugate (ADC), in patients with gastric, colorectal, pancreatic, or biliary cancers
    Ko, Andrew H.
    Coveler, Andrew L.
    Schlechter, Benjamin L.
    Bekaii-Saab, Tanios S.
    Wolpin, Brian M.
    Clark, Jeffrey William
    Cheng, Yi-Lin
    Cheng, Ting-Ying
    Langecker, Peter J.
    Lin, Shih-Yao
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
  • [47] Sacituzumab govitecan (IMMU-132), an anti-Trop-2-SN-38 antibody-drug conjugate (ADC) for the treatment of relapsed/refractory, metastatic triple-negative breast cancer (mTNBC): Updated results
    Bardia, A.
    Diamond, J. R.
    Mayer, I. A.
    Isakoff, S. J.
    Abramson, V.
    Starodub, A. N.
    O'Shaughnessy, J.
    Kalinsky, K.
    Moroose, R.
    Shah, N.
    Juric, D.
    Shapiro, G. I.
    Guarino, M.
    Ocean, A. J.
    Messersmith, W. A.
    Berlin, J. D.
    Wegener, W. A.
    Sharkey, R. M.
    Goldenberg, D. M.
    Vahdat, L. T.
    CANCER RESEARCH, 2017, 77
  • [48] Preliminary Results of a Phase 2 Study of Camidanlumab Tesirine (Cami), a Novel Pyrrolobenzodiazepine-Based Antibody-Drug Conjugate, in Patients With Relapsed or Refractory Hodgkin Lymphoma
    Herrera, Alex F.
    Carlo-Stella, Carmelo
    Collins, Graham P.
    Maddocks, Kami J.
    Bartlett, Nancy L.
    Savage, Kerry J.
    Caimi, Paolo F.
    Hess, Brian T.
    Zinzani, Pier Luigi
    Cruz, Hans G.
    Wang, Luqiang
    Feingold, Jay
    Wuerthner, Jens
    Ansell, Stephen M.
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2021, 19 (02) : 13 - 14
  • [49] Preliminary Results of a Phase 2 Study of Camidanlumab Tesirine (Cami), a Novel Pyrrolobenzodiazepine-Based Antibody-Drug Conjugate, in Patients with Relapsed or Refractory Hodgkin Lymphoma
    Herrera, Alex F.
    Carlo-Stella, Carmelo
    Collins, Graham P.
    Maddocks, Kami J.
    Bartlett, Nancy L.
    Savage, Kerry J.
    Caimi, Paolo F.
    Hess, Brian T.
    Zinzani, Pier Luigi
    Cruz, Hans G.
    Wang, Luqiang
    Feingold, Jay
    Wuerthner, Jens
    Ansell, Stephen M.
    BLOOD, 2020, 136
  • [50] A phase II study of trastuzumab-DM1 (T-DM1), a HER2 antibody-drug conjugate (ADC), in patients (pts) with HER2+metastatic breast cancer (MBC): Final results
    Vogel, C. L.
    Burris, H. A.
    Limentani, S.
    Borson, R.
    O'Shaughnessy, J.
    Vukelja, S.
    Agresta, S.
    Klencke, B.
    Birkner, M.
    Rugo, H.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
12345